AZD-3514 is a down-regulator of androgen receptors. The drug was synthesized by AstraZeneca for the treatment of castrate-resistant prostate cancer and even reached phase I, however, its development was terminated.

Verdiperstat (formerly known as AZD 3241) was developed as a selective inhibitor of myeloperoxidase, an enzyme that acts as a key driver of pathological oxidative stress and inflammation in the brain. Verdiperstat was studied in patients with a number of neurodegenerative disorders, including multiple system atrophy and Parkinson's disease. Verdiperstat participated in phase II clinical trials for both diseases. As a result, studies for Parkinson disease were discontinued. In the case of multiple system atrophy, the drug has received the orphan drug status.

AZD-2461 is an oral inhibitor of PARP-1, which was developed by AstraZeneca as a potential anti-cancer medicine. The drug was tested in phase I clinical patients against solid tumosr, but its development was discontinued.

Ferrous sulfate FE-59 is a salt of radioactive isotope of iron. It has been used to evaluate the absorption of iron into the blood from different dietary iron sources including ferritin and ferrous sulfate. Ferrous sulfate is marketed as an OTC dietary supplement for iron deficiency and iron deficiency anemia when the need for such therapy has been determined by a physician.

DC-0623 is an orally active, selective and ATP-uncompetitive MEK inhibitor with potential antineoplastic activity. GDC-0623 specifically inhibits mitogen-activated protein kinase kinase (MEK or MAP/ERK kinase), resulting in inhibition of growth factor-mediated cell signaling and tumor cell proliferation. In a panel of mutant cancer cell lines, GDC-0623 inhibits cellular proliferation with EC50 values in the low nanomolar range. In vivo, GDC-0623 (40 mg/kg, p.o.) causes potent tumor growth inhibition (TGI) in mouse MiaPaCa-2 (120%), A375 (102%) and HCT116 (115%) xenografts. GDC-0623 had been in phase I clinical trials by Genentech, Inc. for the treatment of Advanced or Metastatic Solid Tumors. However, the clinical development of GDC-0623 was discontinued.

PF-3758309 was developed as an ATP-competitive inhibitor of PAK4. In cells, PF-3758309 inhibits phosphorylation of the PAK4 substrate GEF-H1 (IC50 = 1.3 nM) and anchorage-independent growth of a panel of tumor cell lines (IC50 = 4.7 nM). PF-3758309 blocks the growth of multiple human tumor xenografts, with a plasma EC50 value of 0.4 nM in the most sensitive model. PF-3758309 is antiproliferative and induces apoptosis in an HCT116 tumor model.